It's interesting that he specifically mentions extending healthspan to match lifespan. This is the exact vision I had as a 25 year old - of "squaring the curve," to be able to die healthy. I wrote a book based on what I've learned since that time. I'm now 63.
@SilverFan21k11 ай бұрын
Ty event leaders for hosting this. Dr. Kaeberlein is impressive and super logical.
@Lukas-xb7cx8 күн бұрын
The joke at the beginning about being old was actually really good, I hate this audience for not laughing lol.
@siw51328 ай бұрын
Great delivery, Matt. Articulate, sensationalism-free, cautiously optimistic whilst imparting some hope.
@squamish42445 күн бұрын
The fact that a grounded guy like him still thinks we can crack this means a lot more than whatever Aubrey de Grey spews out for the 1,000 time. As if he has any idea which exact year we have a 50/50 chance of hitting LEV etc.
@SirTenenbaum11 ай бұрын
I'm curious to see how Ora Biomedical, which is only one company of many, progresses in its research.
@livingsmart11 ай бұрын
Amazing talk, thanks! Invest into personal health, invest into aging biology and we could live to 115+ years or more (with some luck)
@SilverFan21k11 ай бұрын
❤️
@squamish42445 күн бұрын
If we make it that far, then a lot of us are hitting 2100 AD. If they haven't cracked aging, period, by then, well...then civilization must have crashed and burned, in which case, we won't be around or want to be around to see that year anyway.
@westfield908 ай бұрын
Sadly I don’t think in the required clinical trials will ever take place in our nation since there just isn’t enough of an incentive for anyone to fund them. Maybe some group in China, India or Japan can conduct them
@squamish42445 күн бұрын
Japan IS doing them. Because it has to. It is where the USA will be in 20 years, and the USA should take note.
@lovelace_the_great6 ай бұрын
Can someone summarize this for me?
@lovelace_the_great6 ай бұрын
The speaker, Matt Kaeberlein, is a leading figure in the field of aging research. He focuses on understanding the biological mechanisms of aging to improve health span. Kaeberlein has published over 250 papers on aging biology and serves as the chief scientific officer at Optuspan Geroscience. Kaeberlein begins by emphasizing that modern medicine has primarily been reactive, focusing on treating diseases after they occur. He advocates for a shift towards proactive health care by targeting the biological aging process, which underlies most age-related diseases. This approach, he argues, could significantly improve health span, the period of life spent in good health. He discusses the concept of "geroscience," the study of the biology connecting aging to functional decline and disease. Understanding these biological mechanisms can lead to interventions that slow aging and thereby delay the onset of age-related diseases. Kaeberlein mentions rapamycin, an FDA-approved drug with substantial effects on lifespan extension in animal models. He notes that rapamycin works even when started in middle age in animals, suggesting its potential applicability for middle-aged humans. Clinical trials are underway to test its efficacy in humans. Despite these advances, Kaeberlein cautions against hype in the field. He is skeptical about the effectiveness of anti-aging supplements, the accuracy of biological aging clocks, and the current state of epigenetic reprogramming. He stresses the need for more research to discover interventions with substantial effects on aging. Looking forward, Kaeberlein believes that while curing aging entirely is unlikely in the near future, we can significantly extend health span using current knowledge. He urges individuals to invest in their health, utilize preventative diagnostics, find knowledgeable doctors, maintain a healthy lifestyle, and educate themselves from credible sources. Finally, he encourages a reevaluation of the risk-reward balance in aging interventions, suggesting that some level of risk might be acceptable for the potential reward of extended health span. Kaeberlein concludes by emphasizing the importance of considering personal risk tolerance in the pursuit of healthier, longer lives.
@megaintegrator9 ай бұрын
we know that we dont know. crapo.
@BR-hi6yt11 ай бұрын
What people are interested in is Yamanka factors and stepping back cell age, not health span definitions, do more exercise, rapamycin and be-more-healthy stuff. We want: STEPPING BACK CELL AGE not lifestyle tips.
@squamish42445 күн бұрын
We do - and the only proven intervention so far is rapamycin. (I would say intravenous NAD+ too, but Kaeberlein doesn't talk about it, for some reason.) He's just saying what we can PROVE right now, not what we can guess. That's all.
@samhouston14836 ай бұрын
So the summary here is we don’t know a damn thing!
@y.g.13139 ай бұрын
very weak typical mainstream talk on what the mainstream can not cure or change: no chronic disease, healthy life beyond 100.
@marjon88811 ай бұрын
I wish I could get the time back I spent listening to this
@SirTenenbaum11 ай бұрын
Why?
@NickWestgate11 ай бұрын
A strange reaction. If you knew who he was, you knew what he would say. If you didn't know, you've now heard a concise summary of the the state of aging science by one of the best in the field.
@anirecapped.11 ай бұрын
@@NickWestgate Not just one of the best but one of the most honest and grounded as well.
@BR-hi6yt11 ай бұрын
Exactly - he is giving us lifestyle tips to lengthen life. Waste of 35 minutes viewing.
@anirecapped.11 ай бұрын
@@BR-hi6yt No, he is giving us the advice for us to remain grounded and measure our expectations in the shorter run.
@6175711 ай бұрын
No
@antoine.-11 ай бұрын
Tf you mean no ???!
@blkshk246611 ай бұрын
@@antoine.- That's what I'm saying.
@sonicsuns11 ай бұрын
Lots of things that were once impossible eventually became possible.
@brewhog11 ай бұрын
No u
@BR-hi6yt11 ай бұрын
Of course its possible to reduce aging at the cellular level, but when are these guys going to get there (never)
@thehealthcaptainsclub442410 ай бұрын
Excellent Overview to follow. Thank you. Welcome @ THE HEALTH CAPTAINS INSTITUTE - INSTITUTE FOR UNIVERSITY AND ACADEMIC MEDICAL CENTER STRATEGY STUDIES AND HEALTHY LONGEVITY AND ONE HEALTH BUSINESS FOR SUSTAINABLE MEDICINE